Session Synopsis: Cancer immunotherapies, though very promising, face a number of challenges as they strive to reach their full potential. These challenges are both technical and scientific in nature and include sensitivity, specificity, efficacy, and cost. Other issues include overcoming production issues and the high cost of developing these therapeutics. This session will address these challenges through the perspective of respected leaders in the field.
Session Chair Profile
M.D., Member – Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center
An internationally renowned expert in virology, immunology and vaccine development, Dr. Corey’s research focuses on herpes viruses and HIV. Current studies include mucosal immunity of viral infections, spatial and functional characterization of tissue resident immune responses at the site of herpesvirus or HIV infection, and spatial dynamics and function of adoptively transferred or vaccine induced T cells. He is the principal investigator of the HIV Vaccine Trials Network, the international collaboration of scientists devoted to developing a globally effective HIV vaccine. Dr. Corey is also past president and director of Fred Hutchinson Cancer Research Center, and a member of the National Academy of Medicine, and the American Academy of Arts and Sciences. Corey received his medical degree from the University of Michigan and his infectious diseases training at the University of Washington.
M.D., CFO & Head of Corporate Development, Juno Therapeutics
Steven D. Harr is our Chief Financial Officer and Head of Corporate Development and joined Juno in April 2014. Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley from May 2010 until he joined Juno. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and Co-Head of Global Healthcare Research. Dr. Harr received a B.A. in Economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.
M.D., President, MD Anderson Cancer Center
His research program has focused on the molecular underpinnings of cancer, aging and degenerative disorders and the translation of such knowledge into clinical advances. Dr. DePinho’s independent scientific career began at the Albert Einstein College of Medicine, where he was the Feinberg Senior Faculty Scholar in Cancer Research. He then joined the Department of Medical Oncology at the Dana-Farber Cancer Institute and the Department of Medicine and Genetics at the Harvard Medical School. He was the founding Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and a Professor of Medicine and Genetics at Harvard Medical School. Dr. DePinho has held numerous board positions and received many honors and awards. He was inducted as a fellow of the American Association of the Advancement of Science in 2014 and the American Association of Cancer Research Class of 2015.
M.D., Professor of Pediatrics and Medicine, Stanford University
Crystal L Mackall MD is Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program and Director of the Parker Institute for Cancer Immunotherapy at Stanford. Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia and her laboratory identified T cell exhaustion as a major factor limiting the efficacy of this novel class of therapeutics. During a 26 year tenure at the National Cancer Institute, Dr. Mackall led numerous cutting edge clinical trials that were characterized by incorporation of deep biologic endpoints that furthered our understanding of fundamental principles of human immunology. She has published over 150 manuscripts in peer-reviewed journals and serves in numerous leadership positions, including co-Leader of the StandUp2Cancer Pediatric Dream Team. She is Board Certified in Pediatrics and Internal Medicine.